| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594281 | American Heart Journal | 2017 | 26 Pages |
Abstract
Evidence-based strategies aiming to simplify HF pharmacotherapy are needed in clinical practice. The ReBIC-1 trial will determine the safety of withdrawing furosemide in stable chronic HF patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Priscila Raupp MD, Luis E. MD, ScD, Madeni RN, Antonio L.P. MD, ScD, Deborah P. MD, Eduardo G. MD, ScD, Jose A. MD, ScD, Ilmar MD, ScD (in memoriam), Luis MD ScD, Luiz C. MD ScD, Lidia Zytynski MD, ScD, Marciane MD, Marcus V. MD, ScD, Roberto T. MD, ScD,